Guru P. Sonpavde MD
Medical Director, Genitourinary Oncology; Assistant Director, Clinical Research Unit; Christopher K. Glanz Chair for Bladder Cancer Research, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, is the Medical Director of Genitourinary Oncology, Assistant Director of the Clinical Research Unit, and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida.
With a focus on drug development and translational research in genitourinary cancers, Dr. Sonpavde has led multiple clinical trials studying novel immunotherapy and targeted drugs, particularly for the treatment of bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Dr. Sonpavde completed his fellowship in medical oncology and hematology at Indiana University.
Disclosures
- Advisory boards: BMS (Bristol Myers Squibb); Genentech; EMD Serono; Merck; Sanofi; Seattle Genetics/Astellas; AstraZeneca; Exelixis; Janssen; Bicycle Therapeutics; Pfizer; Gilead; Scholar Rock; G1 Therapeutics; Eli Lilly/Loxo Oncology; Infinity Pharmaceuticals; Lucence; IMV Technologies
- Research funding: Sanofi iAward); AstraZeneca; Gilead; Helsinn; Lucence; Predicine; Bristol Myers Squibb (BMS); EMD Serono; Jazz Therapeutics; GeneCentric; Kure It; NCI (R21)
- Honoraria:
- Study steering committees: Unpaid: Bristol Myers Squibb (BMS); Bavarian Nordic; Seattle Genetics; QED, G1 Therapeutics Paid: AstraZeneca; EMD Serono; Debiopharm
- DSMC: Mereo BioPharma
- Writing/editing/speaking fees: Wolters Kluwer (UpToDate); Elsevier (PracticeUpdate); Physicians’ Education Resource (PER); OncLive; Research To Practice; Medscape; Cancer Network; Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- ASCO 2018: The Implications of Race in Prostate Cancer
- Bladder Cancer at ASCO 2018
- Biomarkers in GU Cancers
- ASCO GU 2018: A New Prognostic Model for Urothelial Carcinoma
- An Overview of Urothelial Cancer Treatment From ASCO GU 2018
- An Overview of Genomics in GU Oncology
- Key Issues Impacting RCC and Urothelial Cancer: A Review of Recent Trials
- Critical Trial Review in GU Oncology From ASCO 2017
- Sunitinib or PD-1 as Frontline RCC Therapy: A Conceptual Review
- Major Trial Data From ASCO GU 2017: An Overview